{"id":"celecoxib-acetaminohen","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Hepatotoxicity (acetaminophen-related)"},{"rate":null,"effect":"Cardiovascular events (celecoxib-related)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a fixed-dose combination where celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, reduces inflammatory mediators with potentially lower gastrointestinal toxicity compared to non-selective NSAIDs. Acetaminophen works through a different mechanism—inhibiting prostaglandin synthesis centrally and peripherally—providing complementary pain relief and fever reduction. The combination aims to enhance analgesic efficacy while potentially reducing the dose of each individual agent.","oneSentence":"Celecoxib selectively inhibits COX-2 to reduce inflammation and pain, while acetaminophen inhibits prostaglandin synthesis to provide additional analgesic and antipyretic effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:05:16.088Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute and chronic pain management"},{"name":"Inflammatory conditions (e.g., osteoarthritis, rheumatoid arthritis)"}]},"trialDetails":[{"nctId":"NCT06863636","phase":"PHASE3","title":"Efficacy and Safety of Celecoxib/Acetaminophen Versus Celecoxib for Diagnosed Osteoarthritis in Acute Exacerbation","status":"RECRUITING","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2024-09-09","conditions":"Joint Pain, Knee Osteoarthritis, Hip Osteoarthritis","enrollment":231}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cele + Ace"],"phase":"phase_3","status":"active","brandName":"Celecoxib + Acetaminohen","genericName":"Celecoxib + Acetaminohen","companyName":"Laboratorios Silanes S.A. de C.V.","companyId":"laboratorios-silanes-s-a-de-c-v","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Celecoxib selectively inhibits COX-2 to reduce inflammation and pain, while acetaminophen inhibits prostaglandin synthesis to provide additional analgesic and antipyretic effects. Used for Acute and chronic pain management, Inflammatory conditions (e.g., osteoarthritis, rheumatoid arthritis).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}